Logo image of BNTX

BIONTECH SE-ADR (BNTX) Stock Price, Quote, News and Overview

NASDAQ:BNTX - Nasdaq - US09075V1026 - ADR - Currency: USD

117.755  -1.83 (-1.53%)

BNTX Quote, Performance and Key Statistics

BIONTECH SE-ADR

NASDAQ:BNTX (2/20/2025, 1:28:04 PM)

117.755

-1.83 (-1.53%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High131.49
52 Week Low76.53
Market Cap28.23B
Shares239.74M
Float91.82M
Yearly Dividend0
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO10-10 2019-10-10


BNTX short term performance overview.The bars show the price performance of BNTX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 10 20 30

BNTX long term performance overview.The bars show the price performance of BNTX in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 10 -10 20 -20

The current stock price of BNTX is 117.755 USD. In the past month the price increased by 1.99%. In the past year, price increased by 27.25%.

BIONTECH SE-ADR / BNTX Daily stock chart

BNTX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.72 352.72B
AMGN AMGEN INC 14.89 158.49B
GILD GILEAD SCIENCES INC 23.68 136.01B
VRTX VERTEX PHARMACEUTICALS INC 1655.17 123.31B
REGN REGENERON PHARMACEUTICALS 15.22 75.92B
ARGX ARGENX SE - ADR N/A 39.21B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.33B
ONC BEIGENE LTD-ADR N/A 26.17B
NTRA NATERA INC N/A 21.94B
BIIB BIOGEN INC 8.33 20.00B
SMMT SUMMIT THERAPEUTICS INC N/A 16.75B
UTHR UNITED THERAPEUTICS CORP 16.4 16.67B

About BNTX

Company Profile

BNTX logo image BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. The company is headquartered in Mainz, Rheinland-Pfalz and currently employs 6,133 full-time employees. The company went IPO on 2019-10-10. The firm focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The firm is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. The company also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.

Company Info

BIONTECH SE-ADR

An der Goldgrube 12

Mainz RHEINLAND-PFALZ 55131 DE

CEO: Ugur Sahin

Employees: 6133

Company Website: https://www.biontech.com/

Investor Relations: https://investors.biontech.de/

Phone: 4949613190840

BIONTECH SE-ADR / BNTX FAQ

What is the stock price of BIONTECH SE-ADR today?

The current stock price of BNTX is 117.755 USD. The price decreased by -1.53% in the last trading session.


What is the ticker symbol for BIONTECH SE-ADR stock?

The exchange symbol of BIONTECH SE-ADR is BNTX and it is listed on the Nasdaq exchange.


On which exchange is BNTX stock listed?

BNTX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for BIONTECH SE-ADR stock?

27 analysts have analysed BNTX and the average price target is 141.97 USD. This implies a price increase of 20.56% is expected in the next year compared to the current price of 117.755. Check the BIONTECH SE-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is BIONTECH SE-ADR worth?

BIONTECH SE-ADR (BNTX) has a market capitalization of 28.23B USD. This makes BNTX a Large Cap stock.


How many employees does BIONTECH SE-ADR have?

BIONTECH SE-ADR (BNTX) currently has 6133 employees.


What are the support and resistance levels for BIONTECH SE-ADR (BNTX) stock?

BIONTECH SE-ADR (BNTX) has a support level at 119.44 and a resistance level at 121.75. Check the full technical report for a detailed analysis of BNTX support and resistance levels.


Is BIONTECH SE-ADR (BNTX) expected to grow?

The Revenue of BIONTECH SE-ADR (BNTX) is expected to decline by -38.23% in the next year. Check the estimates tab for more information on the BNTX EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy BIONTECH SE-ADR (BNTX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does BIONTECH SE-ADR (BNTX) stock pay dividends?

BNTX does not pay a dividend.


What is the Price/Earnings (PE) ratio of BIONTECH SE-ADR (BNTX)?

BIONTECH SE-ADR (BNTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.05).


What is the Short Interest ratio of BIONTECH SE-ADR (BNTX) stock?

The outstanding short interest for BIONTECH SE-ADR (BNTX) is 2.99% of its float. Check the ownership tab for more information on the BNTX short interest.


BNTX Technical Analysis

ChartMill assigns a technical rating of 8 / 10 to BNTX. When comparing the yearly performance of all stocks, BNTX is one of the better performing stocks in the market, outperforming 80.76% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

BNTX Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to BNTX. BNTX is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

BNTX Financial Highlights

Over the last trailing twelve months BNTX reported a non-GAAP Earnings per Share(EPS) of -2.05. The EPS decreased by -117.52% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -2.08%
ROE -2.44%
Debt/Equity 0.01
Chartmill High Growth Momentum
EPS Q2Q%20.9%
Sales Q2Q%39.04%
EPS 1Y (TTM)-117.52%
Revenue 1Y (TTM)-54.07%

BNTX Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 79% to BNTX. The Buy consensus is the average rating of analysts ratings from 27 analysts.

For the next year, analysts expect an EPS growth of -185.35% and a revenue growth -38.23% for BNTX


Ownership
Inst Owners19.03%
Ins Owners2.05%
Short Float %2.99%
Short Ratio4.03
Analysts
Analysts79.26
Price Target141.97 (20.56%)
EPS Next Y-185.35%
Revenue Next Year-38.23%